Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide + Rituximab in Relapsed/Refractory Follicular Lymphoma
NCT06911502Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of golcadomide in follicular lymphoma (FL), sponsored by Celgene Corporation. Started Jul 2025; status: recruiting.
02
Drugs
golcadomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06911502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911502.